Article3 Biotech2021
Exopolysaccharides from
Article in 3 Biotech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- A New Perspective on the Role ofBiomolecules · 2026Review
- Developing Gut-Healthy Strains for Pets: Probiotic Potential and Genomic Insights of Canine-DerivedMicroorganisms · 2025Article
- Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer.International journal of molecular sciences · 2024Review
- The Crucial Roles of Diet, Microbiota, and Postbiotics in Colorectal Cancer.Current nutrition reports · 2024Review
- Harnessing the Health and Techno-Functional Potential of Lactic Acid Bacteria: A Comprehensive Review.Foods (Basel, Switzerland) · 2024Review
- Multi-Strain Probiotics Enhance the Bioactivity of Cascara Kombucha during Microbial Composition-Controlled Fermentation.Preventive nutrition and food science · 2023Article
- Paraprobiotics: definition, manufacturing methods, and functionality.Food science and biotechnology · 2023Review
- Probiotic-Derived Bioactive Compounds in Colorectal Cancer Treatment.Microorganisms · 2023Review
- Gut microbiota in colorectal cancer development and therapy.Nature reviews. Clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the current study is to ascertain the anticancer activity of exopolysaccharides (EPS) from probiotic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.